



MARYLAND DEPARTMENT OF HEALTH
Medicaid Pharmacy Program

ADVISORY

No. 190

December 11, 2018

Carve-out of Spinraza™ and Cinryze®

Effective Tuesday, January 1, 2019, Spinraza™ and Cinryze® will be carved-out of the HealthChoice Managed Care Benefit and covered by Maryland Medicaid Fee-For Service (FFS) (BIN: 610084, PCN: DRMDPROD and Group ID: MDMEDICAID). Claims for Spinraza™ and Cinryze® must be submitted to FFS, just as claims for other carved-out (behavioral health and antiretroviral) medications.

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Maryland Medicaid Pharmacy Program** (MMPP) has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.